about
sameAs
Aspirin and clopidogrel resistance: an emerging clinical entityPrasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseClopidogrel resistance: myth or reality?Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapyPharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trialDiabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularizationThe potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonistP2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.Antiplatelet therapy and vascular disease: an update.Review of ticagrelor in the management of acute coronary syndromes.Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.Platelet function inhibitors and platelet function testing in neurointerventional procedures.Effect of antiplatelet therapy and platelet function testing on hemorrhagic and thrombotic complications in patients with cerebral aneurysms treated with the pipeline embolization device: a review and meta-analysis.Effects of CYP2C19 and P2Y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel after Acute Ischemic Cerebrovascular Disease.A point-of-care assay to measure platelet aggregation in patients taking clopidogrel.Clopidogrel resistance: fact and fiction.A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humansPlatelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target.Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study.Not all statins interfere with clopidogrel during antiplatelet therapy.Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes.Variability of on-treatment platelet reactivity in patients on clopidogrel.A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention
P2860
Q28194021-EFD7552E-7612-44A6-ACB6-5B00B98F3E25Q28196661-CD34A1D4-3346-4C31-BEA3-21086F7D67F2Q28218055-B182CB86-461C-42B2-8244-13CC009119A1Q33898876-0CD0603D-3F7D-472B-8B80-23D286D0C51BQ34019342-A064F05E-28CC-4684-B392-0C9395B62E11Q36935879-ED898E80-19E4-40D2-870E-17ADC0CCD158Q37167506-4F7D07FF-3C5F-468D-A060-CEE5E439852BQ37380507-63376B36-4116-4918-9020-1DF6DD40E71BQ37486601-12607253-AE23-4F4A-BD52-28002317984FQ37552005-493C4E2E-D55E-42DF-914B-9292BB919383Q37562606-CE05198E-FDC7-4F87-9014-084B0D828928Q37838100-5AF9B68D-91BC-402C-BEDF-26C2DFCDBBAAQ38038255-80C378DE-9F09-48E8-83C6-C08E67530DBDQ38065124-2A216637-EF17-4FAA-8767-C2C15D5B710CQ38233284-939552FA-90D2-4492-9D57-D6248D3AF8F7Q38266831-1D7DE4D4-8B46-438C-AA7F-64F3643F7288Q40044394-B8F10554-DD17-4B60-8DA9-2DC371A8FBACQ40329955-A04914EE-0C13-4BDB-AE16-A77075F4D24DQ40347840-FFB6414B-F58B-4D34-9597-EDD1F0D48223Q41868121-EF6E2800-56E3-4FF0-B10B-F717B642CC00Q44479790-9CEF12EF-5FAE-4504-93C6-6EC985B99DAAQ46184936-A50F7600-A84B-46B4-91EA-AC7B588D9080Q46542883-E5925821-84F6-4302-936A-8AB7CF233B1EQ46651379-494507E4-826B-43A9-A359-A17EF53B927BQ46653236-9946323F-6755-41DF-BBC2-E4D87B7C5C3FQ48182667-C124BA68-29FC-4E2F-92AF-F9ADBA88A667Q57774051-53B88921-D1B6-4523-A38B-4CD3DB72B53C
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Durability of platelet inhibition by clopidogrel
@ast
Durability of platelet inhibition by clopidogrel
@en
Durability of platelet inhibition by clopidogrel
@nl
type
label
Durability of platelet inhibition by clopidogrel
@ast
Durability of platelet inhibition by clopidogrel
@en
Durability of platelet inhibition by clopidogrel
@nl
prefLabel
Durability of platelet inhibition by clopidogrel
@ast
Durability of platelet inhibition by clopidogrel
@en
Durability of platelet inhibition by clopidogrel
@nl
P1476
Durability of platelet inhibition by clopidogrel
@en
P2093
Kevin P Bliden
Paul A Gurbel
P304
P356
10.1016/S0002-9149(03)00163-2
P407
P577
2003-05-01T00:00:00Z